Scroll

Announcements

01. 2024
02. 2023
03. 2022
04. 2021
03

2022

Update re. timing of Admission
20/12/2022
Put Option re AZD1656 & £115,586 Subscription
19/12/2022
Clinical Pilot Study for Early Lung Cancer Detection in China
23/11/2022
Conduit Pharmaceuticals Proposed Listing
09/11/2022
Total Voting Rights
31/10/2022
Admission and Total Voting Rights
04/10/2022
Total Voting Rights
30/09/2022
Issue of Consideration Shares and Director Option Exercise
29/09/2022
Holdings in Company
28/09/2022
Interim results for the six months ended 30 June 2022
28/09/2022
Admission and Total Voting Rights
26/09/2022
Subscription, Facility & Publication of Prospectus
21/09/2022
Arcadia Clinical Trial Results Published for Cizzle Biotechnology’s Royalty Bearing interest in AZD1656
18/08/2022
Update on the Development of Proprietary Antibodies for Early-Stage Lung Cancer Detection Tests and Initial Indications in Detecting Other Cancers
05/07/2022
Result of AGM
27/06/2022
Marketing Agreement to Enhance Expansion in the USA
16/06/2022
Posting of Annual Report and Notice of AGM
01/06/2022
Results for the year ended 31 December 2021
30/05/2022
Strategic Alliance to develop and market early lung cancer detection in USA
06/05/2022
Further Research Agreement with the University of York for Cancer Diagnosis and Therapy
11/04/2022
Further positive outcomes from the Arcadia Clinical Trial by SGSC and Excalibur Medicines for Cizzle Biotechnology’s Royalty Bearing interest in AZD1656
07/03/2022
Holdings in Company
18/02/2022
Total Voting Rights
16/02/2022
Acquisition of Royalty Deal in Inflammatory Pulmonary and Cardiovascular Diseases
14/02/2022
Holdings in Company
04/02/2022
Royalty Strategic Alliance for Early Lung Cancer Detection in China
03/02/2022
Holdings in Company
02/02/2022
Holdings in Company
02/02/2022
Holdings in Company
02/02/2022
Holdings in Company
19/01/2022